BCR and COVID-19: In this longitudinal study of the SARS‐CoV‐2–specific MBCs, several key differences in the single‐cell transcriptomic profile and BCR evolution were observed between three patients with severe COVID‐19, and four with mild/moderate disease up to 4 months after the infection.